Clinical and cost-effectiveness, safety and acceptability of c ommunity i ntra v enous a ntibiotic s ervice models: CIVAS systematic review
- PMID: 28428184
- PMCID: PMC5775457
- DOI: 10.1136/bmjopen-2016-013560
Clinical and cost-effectiveness, safety and acceptability of c ommunity i ntra v enous a ntibiotic s ervice models: CIVAS systematic review
Abstract
Objective: Evaluate evidence of the efficacy, safety, acceptability and cost-effectiveness of outpatient parenteral antimicrobial therapy (OPAT) models.
Design: A systematic review.
Data sources: MEDLINE, EMBASE, CINAHL, Cochrane Library, National Health Service (NHS) Economic Evaluation Database (EED), Research Papers in Economics (RePEc), Tufts Cost-Effectiveness Analysis (CEA) Registry, Health Business Elite, Health Information Management Consortium (HMIC), Web of Science Proceedings, International Pharmaceutical Abstracts, British Society for Antimicrobial Chemotherapy website. Searches were undertaken from 1993 to 2015.
Study selection: All studies, except case reports, considering adult patients or practitioners involved in the delivery of OPAT were included. Studies combining outcomes for adults and children or non-intravenous (IV) and IV antibiotic groups were excluded, as were those focused on process of delivery or clinical effectiveness of 1 antibiotic over another. Titles/abstracts were screened by 1 reviewer (20% verified). 2 authors independently screened studies for inclusion.
Results: 128 studies involving >60 000 OPAT episodes were included. 22 studies (17%) did not indicate the OPAT model used; only 29 involved a comparator (23%). There was little difference in duration of OPAT treatment compared with inpatient therapy, and overall OPAT appeared to produce superior cure/improvement rates. However, when models were considered individually, outpatient delivery appeared to be less effective, and self-administration and specialist nurse delivery more effective. Drug side effects, deaths and hospital readmissions were similar to those for inpatient treatment, but there were more line-related complications. Patient satisfaction was high, with advantages seen in being able to resume daily activities and having greater freedom and control. However, most professionals perceived challenges in providing OPAT.
Conclusions: There were no systematic differences related to the impact of OPAT on treatment duration or adverse events. However, evidence of its clinical benefit compared with traditional inpatient treatment is lacking, primarily due to the dearth of good quality comparative studies. There was high patient satisfaction with OPAT use but the few studies considering practitioner acceptability highlighted organisational and logistic barriers to its delivery.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Community IntraVenous Antibiotic Study (CIVAS): protocol for an evaluation of patient preferences for and cost-effectiveness of community intravenous antibiotic services.BMJ Open. 2015 Aug 21;5(8):e008965. doi: 10.1136/bmjopen-2015-008965. BMJ Open. 2015. PMID: 26297374 Free PMC article.
-
Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service.Int J Antimicrob Agents. 2018 Jan;51(1):26-32. doi: 10.1016/j.ijantimicag.2017.03.016. Epub 2017 Jun 30. Int J Antimicrob Agents. 2018. PMID: 28673610
-
Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses.BMJ Open. 2021 Sep 28;11(9):e049733. doi: 10.1136/bmjopen-2021-049733. BMJ Open. 2021. PMID: 34588251 Free PMC article.
-
The history and evolution of outpatient parenteral antibiotic therapy (OPAT).Int J Antimicrob Agents. 2015 Sep;46(3):307-12. doi: 10.1016/j.ijantimicag.2015.07.001. Epub 2015 Jul 17. Int J Antimicrob Agents. 2015. PMID: 26233483 Review.
-
Human Factors approaches to evaluating outpatient parenteral antimicrobial therapy services: A systematic review.Res Social Adm Pharm. 2020 May;16(5):614-627. doi: 10.1016/j.sapharm.2019.08.009. Epub 2019 Aug 5. Res Social Adm Pharm. 2020. PMID: 31401012 Review.
Cited by
-
Stability of Ampicillin plus Ceftriaxone Combined in Elastomeric Infusion Devices for Outpatient Parenteral Antimicrobial Therapy.Antibiotics (Basel). 2023 Feb 22;12(3):432. doi: 10.3390/antibiotics12030432. Antibiotics (Basel). 2023. PMID: 36978299 Free PMC article.
-
The Impact of a Standardized Discharge Process on 30-Day Readmissions for Patients on Outpatient Parenteral Antibiotic Treatment.Hosp Pharm. 2022 Feb;57(1):107-111. doi: 10.1177/0018578720985434. Epub 2020 Dec 29. Hosp Pharm. 2022. PMID: 35521026 Free PMC article.
-
Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.JAC Antimicrob Resist. 2019 Aug 26;1(2):dlz026. doi: 10.1093/jacamr/dlz026. eCollection 2019 Sep. JAC Antimicrob Resist. 2019. PMID: 34222901 Free PMC article. Review.
-
Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy.J Antimicrob Chemother. 2019 Mar 1;74(3):787-790. doi: 10.1093/jac/dky474. J Antimicrob Chemother. 2019. PMID: 30462237 Free PMC article.
-
Outpatient Parenteral Therapy for Complicated Staphylococcus aureus Infections: A Snapshot of Processes and Outcomes in the Real World.Open Forum Infect Dis. 2018 Oct 24;5(11):ofy274. doi: 10.1093/ofid/ofy274. eCollection 2018 Nov. Open Forum Infect Dis. 2018. PMID: 30488039 Free PMC article.
References
-
- Török ME, Chapman AL, Lessing MP, et al. . Outpatient parenteral antimicrobial therapy: recent developments and future prospects. Curr Opin Investig Drugs 2010;11:929–39. - PubMed
-
- Department of Health. National Health Service and Community Care Act 1990. London: The Stationary Office, 1990.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical